
Evidence analysis
Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 7, Status: Authorised
What is established Imuldosa, containing the active substance ustekinumab, is a biologic medicine authorised by the European Medicines Agency (EMA) as of December 12, 2024. It is classified as a biosimilar to Stelara, meaning it is highly similar…
Read →
Evidence analysis
The CBI-M framework for characterization of traumatic brain injury: Evaluation of performance using data from the CENTER-TBI and TRACK-TBI prospective cohort studies
The CBI-M Framework for Traumatic Brain Injury Characterization: An Evidence Dossier What is established Traumatic brain injury (TBI) is recognized as a complex, heterogeneous condition traditionally classified by clinical severity into mild, moderate, or severe categories. This conventional…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 7, Status: Authorised
What is established Afqlir is an authorised biological medicine approved in the European Union on November 13, 2024, for the treatment of several serious eye conditions, including wet age-related macular degeneration (AMD), macular oedema related to retinal vein…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 13, Status: Authorised
What is established Prevenar 20 is a pneumococcal polysaccharide conjugate vaccine authorized for use within the European Union. It targets 20 serotypes of the bacterium Streptococcus pneumoniae, which can cause diseases such as pneumonia, invasive pneumococcal disease, and…
Read →
Evidence analysis
The idea of a university
What is established Higher education in the United States has traditionally aimed to combine intellectual development with character formation, preparing students not only for careers but also for active, responsible citizenship. This dual mission has been articulated since…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Spectrila, asparaginase, Date of authorisation: 14/01/2016, Revision: 7, Status: Authorised
Evidence Dossier: Spectrila (asparaginase) for Acute Lymphoblastic Leukaemia What is established Spectrila is a medicinal product authorized by the European Commission for use in the European Union since January 14, 2016. It contains asparaginase as its active substance…
Read →
Evidence analysis
Terms of reference for the European Sales and Use of Antimicrobials for veterinary medicine (ESUAvet) network
Health & Science Evidence Dossier: European Sales and Use of Antimicrobials for Veterinary Medicine (ESUAvet) Network What is established The European Medicines Agency (EMA) has established the ESUAvet network to monitor the sales and use of antimicrobials in…
Read →
Evidence analysis
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report
Kazakh President’s Grandnephew Donates Sport University to State Following Investigative Report This dossier examines reporting by Radio Azattyq and the Organized Crime and Corruption Reporting Project (OCCRP) on a recent development in Kazakhstan's education sector involving Nurassyl Medeu,…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Foundayo, Orforglipron, Status: Opinion
Human Medicines European Public Assessment Report (EPAR): Foundayo (Orforglipron) - Status: Opinion What is Established On 15 October 2026, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion
New Medicine Yuviwel for Achondroplasia: An Evidence Dossier What is established Yuviwel is a newly developed medicine containing the active substance navepegritide, a prodrug form of C-type natriuretic peptide (CNP). It is intended for the treatment of achondroplasia…
Read →